Patents by Inventor Pascal Furet

Pascal Furet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES
    Publication number: 20130085161
    Abstract: The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1R mediated disorders or diseases.
    Type: Application
    Filed: June 16, 2011
    Publication date: April 4, 2013
    Applicant: NOVARTIS AG
    Inventors: Frederic Berst, Pascal Furet, Andreas Marzinzik, Frederic Stauffer
  • 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
    Patent number: 8389526
    Abstract: The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: March 5, 2013
    Assignee: Novartis AG
    Inventors: Pascal Furet, Clive McCarthy, Joseph Schoepfer, Stefan Stutz
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20130012704
    Abstract: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Qiang DING, Nathanael Schiander GRAY, Bing LI, Yi LIU, Taebo SIM, Tetsuo UNO, Guobao ZHANG, Carole Pissot Soldermann, Werner BREITENSTEIN, Guido BOLD, Giorgio CARAVATTI, Pascal FURET, Vito GUAGNANO, Marc LANG, Paul W. MANLEY, Joseph SCHOEPFER, Carsten SPANKA
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20130012476
    Abstract: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Qiang DING, Nathanael Schiander GRAY, Bing LI, Yi LIU, Taebo SIM, Tetsuo UNO, Guobao ZHANG, Carole Pissot Soldermann, Werner BREITENSTEIN, Guido BOLD, Giorgio CARAVATTI, Pascal FURET, Vito GUAGNANO, Marc LANG, Paul W. MANLEY, Joseph SCHOEPFER, Carsten SPANKA
  • QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS
    Publication number: 20120309766
    Abstract: The invention relates to compounds of formula (I) wherein the substituents are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Inventors: Pascal FURET, Diana GRAUS PORTA, Vito GUAGNANO
  • QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS
    Publication number: 20120309741
    Abstract: The invention relates to compounds of formula (I) wherein the substituents are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Inventors: Pascal FURET, Diana GRAUS PORTA, Vito GUAGNANO
  • Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
    Publication number: 20120289501
    Abstract: The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease.
    Type: Application
    Filed: November 23, 2010
    Publication date: November 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Andrea Vaupel
  • Pyrimidinyl aryl urea derivatives being FGF inhibitors
    Patent number: 8293746
    Abstract: The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: October 23, 2012
    Assignee: Novartis AG
    Inventors: Guido Bold, Pascal Furet, Vito Guagnano
  • Substituted 2-carboxamide cycloamino ureas
    Patent number: 8293753
    Abstract: The present invention relates to compounds of formula I and salts thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameliorated by inhibition of phosphatidylinositol 3-kinase.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: October 23, 2012
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Marc Gerspacher, Robert Mah
  • PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES
    Publication number: 20120263712
    Abstract: The present invention relates to a compound of formula (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
    Type: Application
    Filed: June 5, 2012
    Publication date: October 18, 2012
    Applicant: NOVARTIS AG
    Inventors: Robin Alec FAIRHURST, Vito GUAGNANO, Patricia IMBACH, Giorgio CARAVATTI, Pascal FURET
  • Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
    Patent number: 8273882
    Abstract: The invention relates to compounds of formula (I) wherein the substituents are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 25, 2012
    Assignee: Novartis AG
    Inventors: Pascal Furet, Diana Graus Porta, Vito Guagnano
  • Imidazoquinolines as lipid kinase inhibitors
    Publication number: 20120207751
    Abstract: The invention relates to a combination comprising compounds of formula (I) and one or more other antiproliferative compounds, hormones or radiation, pharmaceutical preparations comprising the combination thereof, and the application thereof in a process for the treatment of tumors.
    Type: Application
    Filed: April 23, 2012
    Publication date: August 16, 2012
    Applicant: NOVARTIS AG
    Inventors: Carlos Garcia-Echeverria, Frédéric Stauffer, Pascal Furet
  • Pyrrolidine-1,2-dicarboxamide derivatives
    Patent number: 8227462
    Abstract: The present invention relates to a compound of formula (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: July 24, 2012
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, Vito Guagnano, Patricia Imbach, Giorgio Caravatti, Pascal Furet
  • PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS
    Publication number: 20120184561
    Abstract: The invention relates to compounds of the formula I, wherein the moieties R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, and salts thereof; as well as their use, methods of use for them and methods of their synthesis, and the like. The compounds are protein kinase inhibitors and can, inter alia, be used in the treatment of various proliferative diseases.
    Type: Application
    Filed: July 13, 2011
    Publication date: July 19, 2012
    Inventors: Guido BOLD, Pascal FURET, Vito GUAGNANO, Clive McCARTHY, Andrea VAUPEL
  • ETHER DERIVATIVES OF BICYCLIC HETEROARYLS
    Publication number: 20120165310
    Abstract: The invention relates to compounds of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease.
    Type: Application
    Filed: September 10, 2010
    Publication date: June 28, 2012
    Applicant: NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Vito Guagnano, Jiang Songchun, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Frederic Stauffer, Stefan Stutz, Andrea Vaupel
  • TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS
    Publication number: 20120149661
    Abstract: The invention relates to tetra-substituted heteroarylic compounds of the formula (I) wherein X1, X3 and X4 are independently C or N, Y is C—H, N—H or N, wherein the total number of nitrogen atoms represented by X1, X3, X4 and Y is 1 or 2; rings A and B are independently selected from phenyl or pyridyl; R1, R4, R?, R?, n and m are as defined herein. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: August 24, 2010
    Publication date: June 14, 2012
    Applicant: NOVARTIS AG
    Inventors: Guido Bold, Pascal Furet, Francois Gessier, Joerg Kallen, Joanna Hergovich Lisztwan, Keiichi Masuya, Andrea Vaupel
  • Quinoxaline derivatives as tyrosine kinase activity inhibitors
    Patent number: 8193189
    Abstract: The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: June 5, 2012
    Assignee: Novartis AG
    Inventors: Marc Gerspacher, Pascal Furet, Eric Vangrevelinghe, Carole Pissot Sondermann, Christoph Gaul, Philipp Holzer
  • BICYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20110301157
    Abstract: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
    Type: Application
    Filed: August 17, 2011
    Publication date: December 8, 2011
    Inventors: Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul W. Manley, Andrea Vaupel, Carole Pissot Soldermann, Francois Gessier, Christian Schnell, Amanda Jane Littlewood-Evans, Prasad Koteswara Kapa, Joginder S. Bajwa, Xinglong Jiang
  • 3-imidazolyl-indoles for the treatment of proliferative diseases
    Patent number: 8053457
    Abstract: The invention relates to 3-heterocyclyl indolyl compounds of formula I capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively: wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: November 8, 2011
    Assignee: Novartis AG
    Inventors: Andreas Boettcher, Nicole Buschmann, Pascal Furet, Jean-Marc Groell, Jorg Kallen, Joanna Hergovich Lisztwan, Keiichi Masuya, Lorenz Mayr, Andrea Vaupel
  • 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors
    Publication number: 20110251202
    Abstract: The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 13, 2011
    Applicant: NOVARTIS AG
    Inventors: Carlos GARCIA-ECHEVERRIA, Frédéric STAUFFER, Pascal FURET